Xollent Biotech is a VC backed leading exosome therapeutics platform company. Our portfolio covers oncology, cardiology, and cosmetic applications. Our unique technology allows us to deliver the right amount of exosomes to the right place (either it is a that tumor needs to be eradicated or an injured heart that needs repair). The company has acquired important proof of concept and is currently working on multiple preINDs to initiate human trials.